Insmed (INSM) Competitors $104.94 +2.07 (+2.02%) As of 12:53 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock INSM vs. TAK, ARGX, BNTX, ONC, TEVA, SMMT, ITCI, GMAB, RDY, and MRNAShould you be buying Insmed stock or one of its competitors? The main competitors of Insmed include Takeda Pharmaceutical (TAK), argenex (ARGX), BioNTech (BNTX), BeOne Medicines (ONC), Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), and Moderna (MRNA). These companies are all part of the "pharmaceutical products" industry. Insmed vs. Its Competitors Takeda Pharmaceutical argenex BioNTech BeOne Medicines Teva Pharmaceutical Industries Summit Therapeutics Intra-Cellular Therapies Genmab A/S Dr. Reddy's Laboratories Moderna Insmed (NASDAQ:INSM) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, media sentiment, earnings and analyst recommendations. Is INSM or TAK more profitable? Takeda Pharmaceutical has a net margin of 2.36% compared to Insmed's net margin of -265.93%. Takeda Pharmaceutical's return on equity of 10.64% beat Insmed's return on equity.Company Net Margins Return on Equity Return on Assets Insmed-265.93% -446.98% -52.70% Takeda Pharmaceutical 2.36%10.64%5.14% Which has higher earnings & valuation, INSM or TAK? Takeda Pharmaceutical has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInsmed$363.71M54.74-$913.77M-$5.95-17.64Takeda Pharmaceutical$4.58T0.01$712.33M$0.2266.66 Do analysts rate INSM or TAK? Insmed currently has a consensus target price of $108.07, indicating a potential upside of 2.98%. Given Insmed's higher possible upside, research analysts plainly believe Insmed is more favorable than Takeda Pharmaceutical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Insmed 0 Sell rating(s) 0 Hold rating(s) 17 Buy rating(s) 0 Strong Buy rating(s) 3.00Takeda Pharmaceutical 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals and insiders believe in INSM or TAK? 9.2% of Takeda Pharmaceutical shares are owned by institutional investors. 3.0% of Insmed shares are owned by company insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the media favor INSM or TAK? In the previous week, Insmed had 16 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 20 mentions for Insmed and 4 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 1.29 beat Insmed's score of 0.77 indicating that Takeda Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 12 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Takeda Pharmaceutical 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, INSM or TAK? Insmed has a beta of 0.9, meaning that its share price is 10% less volatile than the S&P 500. Comparatively, Takeda Pharmaceutical has a beta of 0.23, meaning that its share price is 77% less volatile than the S&P 500. SummaryTakeda Pharmaceutical beats Insmed on 9 of the 15 factors compared between the two stocks. Get Insmed News Delivered to You Automatically Sign up to receive the latest news and ratings for INSM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INSM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INSM vs. The Competition Export to ExcelMetricInsmedMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$19.89B$2.92B$5.56B$9.26BDividend YieldN/A2.43%4.23%4.03%P/E Ratio-17.6220.2728.5819.56Price / Sales54.74298.79434.47183.65Price / CashN/A43.1536.0257.93Price / Book65.597.668.165.58Net Income-$913.77M-$55.11M$3.24B$257.82M7 Day Performance8.78%0.03%-0.64%-0.39%1 Month Performance3.30%7.47%4.93%7.80%1 Year Performance34.58%-3.28%26.04%12.95% Insmed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INSMInsmed3.8012 of 5 stars$104.94+2.0%$108.07+3.0%+32.8%$19.89B$363.71M-17.621,271News CoverageInsider TradeTAKTakeda Pharmaceutical2.033 of 5 stars$15.07-1.8%N/A+10.0%$47.95B$30.09B68.5047,455Positive NewsARGXargenex4.3872 of 5 stars$546.04+0.5%$728.06+33.3%+20.4%$33.34B$2.25B33.691,599Analyst RevisionBNTXBioNTech1.6362 of 5 stars$110.05+0.0%$137.86+25.3%+31.3%$26.45B$2.98B-32.376,772Analyst ForecastONCBeOne Medicines2.4974 of 5 stars$240.99-1.8%$320.67+33.1%N/A$26.41B$4.18B-64.7811,000TEVATeva Pharmaceutical Industries3.8376 of 5 stars$16.84-1.0%$24.13+43.3%-6.1%$19.31B$16.54B-14.6436,830SMMTSummit Therapeutics2.8575 of 5 stars$22.61-7.9%$34.67+53.3%+157.2%$16.79B$700K-66.50110Gap UpITCIIntra-Cellular Therapies0.9091 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560GMABGenmab A/S3.9035 of 5 stars$20.52+1.1%$37.60+83.2%-20.3%$13.16B$3.12B11.662,682Positive NewsAnalyst RevisionRDYDr. Reddy's Laboratories2.7714 of 5 stars$15.08flat$16.95+12.4%-9.5%$12.59B$3.81B22.8527,811Positive NewsMRNAModerna4.3521 of 5 stars$29.90-1.9%$46.61+55.9%-74.0%$11.56B$3.24B-3.425,800Analyst ForecastAnalyst Revision Related Companies and Tools Related Companies Takeda Pharmaceutical Competitors argenex Competitors BioNTech Competitors BeOne Medicines Competitors Teva Pharmaceutical Industries Competitors Summit Therapeutics Competitors Intra-Cellular Therapies Competitors Genmab A/S Competitors Dr. Reddy's Laboratories Competitors Moderna Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INSM) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredCentral Banks Are Hoarding Gold – Should You?The AI boom isn’t just transforming technology—it’s redefining global power, increasing government debt, and u...Lear Capital | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredAll New Social Security Numbers coming July 23?To All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Insmed, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Insmed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
